Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Armstrong

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Clinical Liver Disease|April 18, 2019
Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedsideMatthew J Armstrong,
Journal of Hepatology|June 24, 2019
Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'Matthew J Armstrong, Giulio Marchesini
Alimentary Pharmacology & Therapeutics|October 16, 2018
Editorial: predicting hepatic encephalopathy after TIPSS-is multimodal cerebral MRI the answer?Matthew J Armstrong, Dhiraj Tripathi
Journal of the Royal Society of Medicine|April 9, 2013
Mobile health use in low- and high-income countries: an overview of the peer-reviewed literatureAndrew Bastawrous, Matthew J Armstrong
The New England Journal of Medicine|October 24, 2008
Electronic health records in ambulatory careMatthew J Armstrong, Caroline Booth
Clinical Medicine (London, England)|September 16, 2020
Sarcopenia in cirrhosis: A practical overviewAmritpal Dhaliwal, Matthew J Armstrong
Lancet (London, England)|July 15, 2015
Trials of obeticholic acid for non-alcoholic steatohepatitisMatthew J Armstrong, Philip N Newsome
Alimentary Pharmacology & Therapeutics|February 13, 2024
Editorial: Enhancing frailty assessment in liver transplantation candidates-The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' replyMatthew J Armstrong, Felicity R Williams
Hepatology Communications|February 7, 2018
Lean NAFLD: A not so benign condition?Lisa B VanWagner, Matthew J Armstrong
Transplantation|November 22, 2012
Tobacco smoking and solid organ transplantationChris Corbett, Matthew J Armstrong, James Neuberger
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Clinical Liver Disease|April 18, 2019
Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedsideMatthew J Armstrong,
Journal of Hepatology|June 24, 2019
Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'Matthew J Armstrong, Giulio Marchesini
Alimentary Pharmacology & Therapeutics|October 16, 2018
Editorial: predicting hepatic encephalopathy after TIPSS-is multimodal cerebral MRI the answer?Matthew J Armstrong, Dhiraj Tripathi
Journal of the Royal Society of Medicine|April 9, 2013
Mobile health use in low- and high-income countries: an overview of the peer-reviewed literatureAndrew Bastawrous, Matthew J Armstrong
The New England Journal of Medicine|October 24, 2008
Electronic health records in ambulatory careMatthew J Armstrong, Caroline Booth
Clinical Medicine (London, England)|September 16, 2020
Sarcopenia in cirrhosis: A practical overviewAmritpal Dhaliwal, Matthew J Armstrong
Lancet (London, England)|July 15, 2015
Trials of obeticholic acid for non-alcoholic steatohepatitisMatthew J Armstrong, Philip N Newsome
Alimentary Pharmacology & Therapeutics|February 13, 2024
Editorial: Enhancing frailty assessment in liver transplantation candidates-The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' replyMatthew J Armstrong, Felicity R Williams
Hepatology Communications|February 7, 2018
Lean NAFLD: A not so benign condition?Lisa B VanWagner, Matthew J Armstrong
Transplantation|November 22, 2012
Tobacco smoking and solid organ transplantationChris Corbett, Matthew J Armstrong, James Neuberger
Pageof 12